293 related articles for article (PubMed ID: 21726984)
1. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia.
Jaruratanasirikul S; Kositpantawong N; Jullangkoon M; Aeinlang N; Wongpoowarak W
J Med Assoc Thai; 2013 Oct; 96(10):1283-9. PubMed ID: 24350408
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S; Punyo J
Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
[TBL] [Abstract][Full Text] [Related]
5. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S
J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
[TBL] [Abstract][Full Text] [Related]
7. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
[TBL] [Abstract][Full Text] [Related]
10. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of imipenem in critically ill patients with ventilator-associated pneumonia.
Jaruratanasirikul S; Aeinlang N; Jullangkoon M; Wongpoowarak W
J Med Assoc Thai; 2013 May; 96(5):551-7. PubMed ID: 23745309
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
Ariano RE; Nyhlén A; Donnelly JP; Sitar DS; Harding GK; Zelenitsky SA
Ann Pharmacother; 2005 Jan; 39(1):32-8. PubMed ID: 15598967
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
15. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
[TBL] [Abstract][Full Text] [Related]
17. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
18. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
